These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2430652)

  • 1. [Advanced cancer of the prostate. Treatment with an LH-RH agonist, D-Trp-6-LH-RH].
    Mathé G; Misset JL; Vovan ML; Machover D
    Bull Cancer; 1986; 73(1):31-5. PubMed ID: 2430652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.
    Mathé G; Schally AV; Comaru-Schally AM; Mauvernay RY; Vovan ML; Machover D; Misset JL; Court B; Bouchard P; Duchier J
    Prostate; 1986; 9(4):327-42. PubMed ID: 2947053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
    Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Ureta-Sanchez S; Berea Dominguez H; Graef-Sanchez A; Becerril Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1985; 7(1):21-30. PubMed ID: 2934692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
    Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
    Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW; Schally AV
    Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
    Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Berea-Dominguez H; Graef-Sanchez A; Becerril-Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1986; 9(2):207-15. PubMed ID: 2944084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A; Germinale T
    Am J Clin Oncol; 1988; 11 Suppl 2():S129-31. PubMed ID: 2977269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An oriented phase-II trial of D-Trp6-LH-RH in patients with prostatic carcinoma.
    Mathé G; Vo Van ML; Duchier J; Misset JL; Morin P; Keiling R; Schwarzenberg L; Kerbrat P; Achille E; Tronc JC
    Med Oncol Tumor Pharmacother; 1984; 1(2):119-22. PubMed ID: 6242478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of prostatic cancers by periodic administration of a delayed-release preparation of D-Trp(6)-LHRH].
    Roger M; Duchier J; Lahlou N; Schally AV
    Ann Urol (Paris); 1986; 20(2):109-12. PubMed ID: 2424359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
    St Arnaud R; Lachance R; Dupont A; Labrie F
    J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of prostatic cancer with an LH-RH agonist: the D Trp6 LH-RH. Preliminary results in 30 cases].
    Steg A; Chiche R; Boccon-Gibod L; Debré B; Duchier J; Schally AV
    Ann Urol (Paris); 1984 Dec; 18(6):388-92. PubMed ID: 6241820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An analog of gonadoliberin in the treatment of prostatic carcinoma].
    Mathé G; Schally AV; Vo Van ML; Duchier J; Misset JL; Keiling R
    Presse Med; 1984 Jun; 13(23):1443-5. PubMed ID: 6233591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of prostatic cancer with a depot form of a luteinizing hormone-releasing hormone analogue.
    Giuliani L; Barreca T; Giberti C; Franceschini R; Martorana G; Brancadoro MT; Salvemini M; Rolandi E
    Eur Urol; 1986; 12(6):390-4. PubMed ID: 2949979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    Cancer Res; 1990 Jun; 50(12):3716-21. PubMed ID: 2160323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH.
    Zalatnai A; Paz-Bouza JI; Redding TW; Schally AV
    Prostate; 1988; 12(1):85-98. PubMed ID: 2894651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.